ArticlePloS one2011
H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S?
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 105 citations in OpenAlex.
- S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/HJournal of translational medicine · 2026Article
- Potential therapeutic applications of medical gases in cancer treatment.Medical gas research · 2025Review
- S-propargyl-cysteine attenuates temporomandibular joint osteoarthritis by regulating macrophage polarization via Inhibition of JAK/STAT signaling.Molecular medicine (Cambridge, Mass.) · 2025Article
- An iridium(III) complex-based luminogenic probe for high-throughput screening of hydrogen sulfide donors in living cells.Communications chemistry · 2024Article
- Concurrent Subcellular Delivery of Hydrogen Sulfide and a Payload with Near-Infrared Light.JACS Au · 2024Article
- The potential role of hydrogen sulfide in cancer cell apoptosis.Cell death discovery · 2024Review
- Dual targeting of HHeliyon · 2023Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Article
- Hydrogen sulfide attenuates lung injury instigated by Bisphenol-A via suppressing inflammation and oxidative stress.BMC pharmacology & toxicology · 2022Article
- Article
- Hydrogen Sulfide Biology and Its Role in Cancer.Molecules (Basel, Switzerland) · 2022Review
- The Protective Effects of Hydrogen Sulfide New Donor MethylMolecules (Basel, Switzerland) · 2022Article
- A novel dendritic mesoporous silica based sustained hydrogen sulfide donor for the alleviation of adjuvant-induced inflammation in rats.Drug delivery · 2021Article
- The Hidden Role of Hydrogen Sulfide Metabolism in Cancer.International journal of molecular sciences · 2021Review
- The Preparation of a Novel Poly(Lactic Acid)-Based Sustained HPharmaceutics · 2021Article
- Transcriptional network constituted of CBP, Ku70, NOX2, and BAX prevents the cell death of necrosis, paraptosis, and apoptosis in human melanoma.Cell death discovery · 2021Article
- Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.Cancers · 2021Review
- Mistimed HBiomedical reports · 2020Article
- An Appraisal of Developments in Allium Sulfur Chemistry: Expanding the Pharmacopeia of Garlic.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundS-propargyl-cysteine (SPRC), an H(2)S donor, is a structural analogue of S-allycysteine (SAC). It was investigated for its potential anti-cancer effect on SGC-7901 gastric cancer cells and the possible mechanisms that may be involved. METHODS AND
findingsSPRC treatment significantly decreased cell viability, suppressed the proliferation and migration of SPRC-7901 gastric cancer cells, was pro-apoptotic as well as caused cell cycle arrest at the G(1)/S phase. In an in vivo study, intra-peritoneal injection of 50 mg/kg and 100 mg/kg of SPRC significantly reduced tumor weights and tumor volumes of gastric cancer implants in nude mice, with a tumor growth inhibition rate of 40-75%. SPRC also induced a pro-apoptotic effect in cancer tissues and elevated the expressions of p53 and Bax in tumors and cells. SPRC treatment also increased protein expression of cystathione-γ-lyase (CSE) in cells and tumors, and elevated H(2)S levels in cell culture media, plasma and tumoral CSE activity of gastric cancer-induced nude mice by 2, 2.3 and 1.4 fold, respectively. Most of the anti-cancer functions of SPRC on cells and tumors were significantly suppressed by PAG, an inhibitor of CSE activity.
conclusionsTaken together, the results of our study provide insights into a novel anti-cancer effect of H(2)S as well as of SPRC on gastric cancer through inducing the activity of a new target, CSE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.